Aequus Pharmaceuticals Inc - Asset Resilience Ratio
Aequus Pharmaceuticals Inc (AQS) has an Asset Resilience Ratio of 4.11% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2023)
This chart shows how Aequus Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check AQS PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Aequus Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Aequus Pharmaceuticals Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$44.85K | 4.11% |
| Total Liquid Assets | CA$44.85K | 4.11% |
Asset Resilience Insights
- Limited Liquidity: Aequus Pharmaceuticals Inc maintains only 4.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Aequus Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Aequus Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940 |
Drug Manufacturers - Specialty & Generic | 9.11% |
Annual Asset Resilience Ratio for Aequus Pharmaceuticals Inc (2017–2023)
The table below shows the annual Asset Resilience Ratio data for Aequus Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 4.13% | CA$44.85K ≈ $32.44K |
CA$1.09 Million ≈ $785.76K |
+1.48pp |
| 2022-12-31 | 2.65% | CA$44.85K ≈ $32.44K |
CA$1.69 Million ≈ $1.22 Million |
+1.62pp |
| 2021-12-31 | 1.03% | CA$44.89K ≈ $32.47K |
CA$4.35 Million ≈ $3.15 Million |
+1.03pp |
| 2020-12-31 | 0.00% | CA$123.00 ≈ $88.98 |
CA$3.13 Million ≈ $2.27 Million |
-31.81pp |
| 2017-12-31 | 31.81% | CA$850.00K ≈ $614.88K |
CA$2.67 Million ≈ $1.93 Million |
-- |
About Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceu… Read more